Monday, April 19, 2010

Amgen Announces Webcast of 2010 First Quarter Financial Results

THOUSAND OAKS, Calif., April 19, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that it plans to report its first quarter financial results on Wednesday, April 21, 2010 after the close of the U.S.  financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team.

Read the rest of this entry

Posted in Press Releases

Monday, April 19, 2010

Amgen Preclinical Study Demonstrated Anti-Tumor Activity in Mammary Tumor Model

THOUSAND OAKS, Calif., April 19, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL. These molecules have a comparable mechanism of action to denosumab. The study was presented today in a late-breaking abstract at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

Read the rest of this entry

Posted in Press Releases

Sunday, April 18, 2010

Analysis of Vectibix(R) Study Using New Gene Technology Helps to Advance Prospects for Personalized Medicine

--Nine Genes Beyond KRAS Investigated As Potential Predictive Biomarkers For Metastatic Colorectal Cancer Therapy --ABSTRACT NUMBER: LBA 8791

THOUSAND OAKS, Calif., April 18, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced detailed results from a new biomarker analysis of the pivotal Phase 3 “408” trial of Vectibix(R) (panitumumab) plus best supportive care (BSC) compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer (mCRC). Highlighted results were presented at the opening press conference at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

Read the rest of this entry

Posted in Press Releases

Monday, April 12, 2010

Amgen Highlights Biomarker and Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting

Key RANK Ligand Preclinical Data and Vectibix Biomarker Data Will Be Presented

THOUSAND OAKS, Calif., April 12, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that results from several preclinical studies investigating potential new cancer agents and a comprehensive biomarker analysis will be presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C. from April 17 - 21, 2010.

Read the rest of this entry

Posted in Press Releases

Monday, March 08, 2010

Amgen to Present at the Cowen and Company 30th Annual Healthcare Conference

THOUSAND OAKS, Calif., March 8, 2010 /PRNewswire via COMTEX/ —Amgen (Nasdaq: AMGN) will present at the Cowen and Company 30th Annual Healthcare Conference on Wednesday, March 10, 2010 at the Boston Marriott Copley Place, Boston, Mass., beginning at 9:30 a.m. Eastern Time. James Daly, Amgen’s Senior Vice President of North American Commercial Operations, will present.  Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors.

Read the rest of this entry

Posted in Press Releases